Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AbbVie Inc (NYSE:ABBV)

65.10
Delayed Data
As of Apr 25
 +0.44 / +0.68%
Today’s Change
55.06
Today|||52-Week Range
68.12
+3.96%
Year-to-Date
Gilead (GILD) Q1 Earnings: Stock Likely to Beat Estimates?
Apr 25 / Zacks.com - Paid Partner Content
AbbVie (ABBV) Presents Positive Data on HCV Combination Drug
Apr 21 / Zacks.com - Paid Partner Content
Sawgrass Asset Management Llc Buys Nike, Illinois Tool Works, The Cooper, Sells Dolla...
Apr 25 / GuruFocus News - Paid Partner Content
What's in Store for AbbVie (ABBV) this Earnings Season?
Apr 21 / Zacks.com - Paid Partner Content
Biogen (BIIB) Q1 Earnings & Sales Top, Spinraza Sales Strong
Apr 25 / Zacks.com - Paid Partner Content
What's in Store for Biogen (BIIB) this Earnings Season?
Apr 20 / Zacks.com - Paid Partner Content
Breaking Down the 2-Stage Dividend Discount Model for Beginners
Apr 24 / GuruFocus News - Paid Partner Content
AbbVie's (ABBV) Cancer Candidate Fails in Phase III Studies
Apr 20 / Zacks.com - Paid Partner Content
Is Pain Ahead for Healthcare ETFs After Weak JNJ Q1?
Apr 24 / Zacks.com - Paid Partner Content
Europe And S&P Futures Higher, Dollar Drops As OPEC Talks Oil Up
Apr 20 / Investing Channel - Paid Partner Content
EQT Midstream Partners, AbbVie, Blackstone Group: 'Mad Money' Lightning Round
Apr 21 / TheStreet.com - Paid Partner Content
FDA arthritis drug rejection hits Eli Lilly shares
Apr 17 / FT.com - Paid Partner Content
AbbVie's Veliparib Missed Primary Endpoints of 2 Clinical Trials
Apr 21 / GuruFocus News - Paid Partner Content
Vertex Pharmaceuticals hails new cystic fibrosis drug
Mar 28 / FT.com - Paid Partner Content